Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 4;7(9):1697–1712. doi: 10.1182/bloodadvances.2022007383

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 2. — AKT inhibition suppresses glycolysis and OXPHOS in MM cells. (A) Immunoblot analysis of HK2 and PKM2 in LME-1, MM1.S, and LP-1 HMCLs treated overnight with 2.5 μM MK2206 AKT inhibitor or left untreated. β-actin served as a loading control. (B) Basal glycolysis in HMCLs and MMPCs (n = 2 patients) treated with 2.5 μM MK2206 (blue bars) for 20 hours or untreated (red bars). Basal ECAR values from the Seahorse XF glycolysis stress test are depicted, and means ± SEM are shown (t test, n = 5-6 measurements). (C) Basal respiration and spare respiratory capacity in HMCLs and MMPCs (n = 2 patients) treated with 2.5 μM MK2206 (blue bars) or untreated (red bars) for 20 hours. OCR values from the Seahorse XF mitochondrial stress test are depicted, and means ± SEM are shown (t-test, n = 5-6 measurements).t test, ∗P < .05; MMPC, primary MM plasma cells.

Figure 2. — AKT inhibition suppresses glycolysis and OXPHOS in MM cells. (A) Immunoblot analysis of HK2 and PKM2 in LME-1, MM1.S, and LP-1 HMCLs treated overnight with 2.5 μM MK2206 AKT inhibitor or left untreated. β-actin served as a loading control. (B) Basal glycolysis in HMCLs and MMPCs (n = 2 patients) treated with 2.5 μM MK2206 (blue bars) for 20 hours or untreated (red bars). Basal ECAR values from the Seahorse XF glycolysis stress test are depicted, and means ± SEM are shown (t test, n = 5-6 measurements). (C) Basal respiration and spare respiratory capacity in HMCLs and MMPCs (n = 2 patients) treated with 2.5 μM MK2206 (blue bars) or untreated (red bars) for 20 hours. OCR values from the Seahorse XF mitochondrial stress test are depicted, and means ± SEM are shown (t-test, n = 5-6 measurements).t test, ∗P < .05; MMPC, primary MM plasma cells.